Brochure
31 Aug 2021

Delpharm Overview

PDF 492 kB
Download

Delpharm is a Worldwide leader in contract manufacturing and development of medicines for pharmaceutical laboratories. It owns 17 manufacturing plants (12 in France, 2 in Italy, 1 in Belgium, 1 in the Netherlands and 1 in Canada) providing the majority of dosage forms available on the market: tablets, syrups, bottles, vials, etc. Delpharm generates €800m in turnover and is wholly-owned by its management. For more information, visit our website: http://www.delpharm.com/

Content provided by our supplier

SAS DELPHARM INDUSTRIE

  • FR
  • 2015
    On CPHI since
  • 4
    Certificates
  • 5000+
    Employees
Company types
Contract Service
View company profile

Other Content from SAS DELPHARM INDUSTRIE (3)

  • GSK agrees to sell its Poznań manufacturing site to Delpharm.

    News GSK agrees to sell its Poznań manufacturing site to Delpharm.

    Poznań, Poland, Thursday 15 October 2020 –GSK and Delpharm announced today they have entered into an agreement under which Delpharm will acquire GSK’s Poznań manufacturing facility in Poland.
    21 Jun 2021
  • Delpharm Overview

    Brochure Delpharm Overview

    Delpharm is a European leader in contract manufacturing and development of medicines for pharmaceutical laboratories. It owns 12 manufacturing plants (nine in France, two in Italy and one in Belgium) providing the majority of dosage forms available on the market: tablets, syrups, bottles, vials, etc. Delpharm generates €500m in turnover and is wholly-owned by its management. For more information, visit our website: http://www.delpharm.com/
  • Delpharm and the Famar Group announce the acquisition by Delpharm of 5 manufacturing sites in France, Canada and the Netherlands.

    News Delpharm and the Famar Group announce the acquisition by Delpharm of 5 manufacturing sites in France, Canada and the Netherlands.

    Delpharm and the Famar Group are pleased to announce the acquisition by Delpharm of 5 manufacturing sites belonging to Famar, in France, Canada and the Netherlands. The transaction signed today covers the French sites located in Orléans (Loiret), L’Aigle (Orne) and Saint-Rémy-sur-Avre (Eure-et-Loire), as well as the Montreal site in Canada and that of Bladel in the Netherlands.
    3 Feb 2020